News - Page 41 of 80 - Yokohama City University

2022-03-30

Analysis of humoral immunity against emerging SARS-CoV-2 variants: a population-based prevalence study in Yokohama, Japan

Background Little is known about the population prevalence of antibodies against emerging immune escape variants of SARS-CoV-2. Methods A population-based prevalence study was conducted in Yokohama City, the most populous municipality of Japan. Quantitative measurements of immunoglobulin G against SARS-CoV-2 spike protein (SP-IgG) and qualitative measurements of neutralization antibodies against the Omicron BA.1 and BA.2 variants were performed.

2022-03-30

HSP90 inhibition overcomes resistance to molecular targeted therapy in BRAFV600E mutant high-grade glioma

Purpose: Molecular targeted therapy using BRAF and/or MEK inhibitors has been applied to BRAFV600E-mutant high-grade gliomas (HGG); however, the therapeutic effect is limited by the emergence of drug resistance.

2022-03-30

Trends in suicide in Japan following the 2019 Coronavirus Pandemic.

During the coronavirus disease 2019 (COVID-19) pandemic, there were concerns that suicides would increase due to changes in lifestyle that restricted human contact in schooling, employment, and social activities.

2022-03-30

Evasion of vaccine-induced humoral immunity by emerging sub-variants of SARS-CoV-2

Background: Emergence of vaccine-escaping SARS-CoV-2 variants is a serious problem for global public health. The currently rampant Omicron has been shown to possess remarkable vaccine escape; however, the selection pressure exerted by vaccines might pave the way for other escape mutants in the near future.